OppenheimerFunds Inc. Boosts Holdings in Nu Skin Enterprises, Inc. (NUS)

OppenheimerFunds Inc. boosted its stake in Nu Skin Enterprises, Inc. (NYSE:NUS) by 80.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 267,285 shares of the company’s stock after purchasing an additional 119,244 shares during the quarter. OppenheimerFunds Inc.’s holdings in Nu Skin Enterprises were worth $20,899,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of NUS. Quantbot Technologies LP grew its holdings in Nu Skin Enterprises by 293.0% in the first quarter. Quantbot Technologies LP now owns 2,071 shares of the company’s stock worth $152,000 after purchasing an additional 1,544 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in shares of Nu Skin Enterprises during the second quarter valued at about $210,000. Greenleaf Trust acquired a new position in shares of Nu Skin Enterprises during the second quarter valued at about $216,000. Stevens Capital Management LP acquired a new position in shares of Nu Skin Enterprises during the second quarter valued at about $221,000. Finally, RBO & Co. LLC acquired a new position in shares of Nu Skin Enterprises during the second quarter valued at about $227,000. Institutional investors and hedge funds own 76.01% of the company’s stock.

In related news, General Counsel D Matthew Dorny sold 2,500 shares of the business’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $79.90, for a total transaction of $199,750.00. Following the transaction, the general counsel now directly owns 33,871 shares in the company, valued at $2,706,292.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Edwina D. Woodbury sold 5,000 shares of the business’s stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $85.02, for a total transaction of $425,100.00. Following the transaction, the director now owns 11,860 shares in the company, valued at $1,008,337.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,850 shares of company stock worth $3,589,888. 5.20% of the stock is owned by corporate insiders.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Nu Skin Enterprises from a “hold” rating to a “sell” rating in a report on Monday, July 2nd. ValuEngine cut shares of Nu Skin Enterprises from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 6th. Stifel Nicolaus upgraded shares of Nu Skin Enterprises from a “sell” rating to a “hold” rating and lifted their price objective for the company from $57.00 to $70.00 in a report on Thursday, August 2nd. They noted that the move was a valuation call. Finally, Jefferies Financial Group set a $98.00 price objective on shares of Nu Skin Enterprises and gave the company a “buy” rating in a report on Friday, August 3rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $85.33.

Shares of NYSE NUS opened at $83.61 on Monday. The stock has a market cap of $4.61 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 2.37 and a beta of 1.11. Nu Skin Enterprises, Inc. has a 1 year low of $59.31 and a 1 year high of $88.68. The company has a quick ratio of 1.19, a current ratio of 1.82 and a debt-to-equity ratio of 0.46.

Nu Skin Enterprises (NYSE:NUS) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.18. Nu Skin Enterprises had a net margin of 5.74% and a return on equity of 25.67%. The firm had revenue of $704.19 million during the quarter, compared to analysts’ expectations of $642.16 million. During the same period last year, the company earned $0.77 earnings per share. The business’s revenue was up 28.0% on a year-over-year basis. research analysts anticipate that Nu Skin Enterprises, Inc. will post 3.61 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 12th. Investors of record on Friday, August 31st were issued a dividend of $0.365 per share. This represents a $1.46 annualized dividend and a yield of 1.75%. The ex-dividend date was Thursday, August 30th. Nu Skin Enterprises’s dividend payout ratio (DPR) is presently 45.20%.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding NUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nu Skin Enterprises, Inc. (NYSE:NUS).

Institutional Ownership by Quarter for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply